Context
Blood cancer patients are typically treated once full-blown cancer has developed. Despite the increasing efficacy of current therapies, in a number of patients, they leave behind small population of resistant tumour cells, that may lead to a relapse.
Challenge
Detecting and characterising early transformation in blood cells would allow researchers worldwide to develop a therapeutic intervention at earlier stages. This would provide better opportunities at controlling the disease and improve long-term survival.
Solution
Focusing on three different types of blood cancer, the Editor project will:
- Identify precise biomarkers for each one of them.
- Understand the mechanisms of initial resistance that lead to relapses